PALOMA3

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

PALOMA3

Jun 16, 2024, 09:13 | Insight

Estela Rodriguez: Subcutaneous vs IV Amivantamab + Lazertinib in NSCLC

Estela Rodriguez shared on X/Twitter: "PALOMA3 Subq (SC) vs IV Amivantamab + Lazertinib, in Refractory EGFR+…

Jun 14, 2024, 14:08 | Blog

Rami Manochakian: Results of PALOMA3 study by Natasha B. Leighl et al

Rami Manochakian shared a post on X: "Hot off the press. Just published in Journal of…

Jun 1, 2024, 12:55 | Societies

Day 1 ASCO24 Highlights by Oncology Brothers

Oncology Brothers shared on X: Day 1 ASCO24 Highlights: 1. CROWN: Lorlatinib in ALK mNSCLC…

All: 3 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023